Biogen

2 articles

Biogen Beats Quarterly Estimates as Newer Drugs Fuel Growth

Biogen reported Q2 profits exceeding estimates driven by rare-disease medicines and Leqembi sales, though legacy MS drug revenue declined. The company cut its 2026 profit forecast following an $5.6 bi

reuters · 2026-07-29 03:03

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

Italy's antitrust authority opened an investigation into Biogen over allegations of abusing its dominant position to exclude rival Sandoz from the multiple sclerosis drug market.

reuters · 2026-05-26 23:27